Overview

Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

Status:
Recruiting

Trial end date:
2024-09-30

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of CU01-1001 administered for 24 weeks in type 2 diabetic nephropathy patients with albuminuria.

Phase:

Phase 2

Details

Lead Sponsor:

Curacle Co., Ltd.